A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
A comprehensive study of Native American breast cancer tissue reveals molecular differences that may impact treatment efficacy. The study found unique patterns in gene mutations and immune system interactions, highlighting the need for personalized therapies.
A US-wide analysis of nearly 50 years of breast cancer data has found a major shift in outcomes and risk, highlighting gaps in prevention and treatment for specific groups. Breast cancer deaths are increasingly affecting younger women, while survival improved among older women over time.
Researchers at UTHealth Houston have discovered a new target for metastatic breast cancer treatments using experimental peptide therapy. The study found that the peptide BLMP6 targets fibulin-4, a protein expressed in high levels in metastatic breast cancers.
Scientists at MUSC Hollings Cancer Center mapped the architecture of healthy breast tissue to uncover early biological changes linked to cancer risk. The study found that body weight and breast density shape the underlying structure of breast tissue, offering new clues about how cancer risk may develop long before tumors form.
The study created a detailed map of breast tissue changes over time, revealing that menopause triggers significant changes that create an environment where cancer cells thrive. The research found that all types of cells decrease in number and divide less often, leading to a more inflammatory immune environment.
Researchers found that Fusobacterium nucleatum accelerates tumor growth and increases cancer cell spread in animal models of human breast cancer, particularly in cells with BRCA1 gene mutations. The study reveals a connection between oral microbes and breast cancer risk and progression.
A phase II clinical trial found that preoperative radiation improved T-cell infiltration and treatment responses in hormone receptor-positive, HER2-negative breast cancer patients. Radiation doses of 24 Gy showed the greatest increase in TCI and tumor clearance, suggesting a potential new strategy for immunotherapy.
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
The addition of tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in HER2-positive metastatic breast cancer patients, particularly those with brain metastasis. This delay allowed for prolonged time off chemotherapy and maintained disease control.
The 48th San Antonio Breast Cancer Symposium brings together over 10,000 global experts to share cutting-edge research on breast cancer discovery, therapeutics, and standard of care. Key findings include the effectiveness of active monitoring for low-risk DCIS patients and a new estrogen-blocking pill that slows cancer progression.
A new AI image-only model has been shown to provide stronger and more precise risk stratification for five-year breast cancer prediction than traditional breast density assessment. The model was trained on 421,499 mammograms and showed a fourfold higher cancer incidence in high-risk women compared to those with average risk.
Researchers identified a cholesterol metabolite called hydroxycholesterol that suppresses the immune system's ability to attack cancer, leading to increased metastasis. The team discovered a line of communication used by immune cells and cancer cells that stimulates breast cancer progression.
A study of over 60,000 US patients with advanced breast cancer found average survival times increased by six to seven months since 2011. Researchers attribute the improvement to more effective treatments, wider diagnosis, and quality of care advancements.
A new study led by Mayo Clinic researchers found that abemaciclib improves survival for people with high-risk, early-stage breast cancer. The drug reduced the risk of death by 15.8% compared to endocrine therapy alone among patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
A recent study published in Radiology found that adding molecular breast imaging to a 3D mammogram improved the ability to detect cancer in dense breast tissue. The combined test detected more cancerous tissue than either technique alone, increasing cancer finds by over double.
Researchers at King's College London have developed a genetic test that can predict which women with abnormal breast cells are most likely to develop invasive breast cancer. The test uses a genetic risk score to estimate a person's inherited likelihood of developing the disease, allowing for more personalized treatment options.
A polygenic risk score (PRS) can predict future breast cancer incidents in women diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). PRS scores were associated with an increased risk of ipsilateral breast cancer, particularly in patients with a family history of breast cancer.
A panel of experts recommends considering hormone replacement therapy for breast cancer survivors with severe menopausal symptoms, citing the need for more patient-centered care. The study suggests that HRT may be safe and beneficial for many women, particularly those with low-risk disease, while minimizing the risk of relapse.
Women who don't attend their first mammogram screening face a 40% higher long-term risk of dying from breast cancer. Targeted interventions are needed to boost adherence and reduce mortality risk among initial non-attenders.
Researchers at the University of Mississippi have developed a new method to deliver cancer therapies directly to triple-negative breast cancer cells. The sugar-coated nanoparticles effectively target this aggressive cancer, which affects young women and disproportionately impacts Black women. The discovery holds promise for treating no...
A clinical trial has identified breast cancer survivors at high risk of recurrence due to dormant cells and successfully treated them with existing drugs. The study shows a 90% survival rate without disease recurrence in patients who received one drug and 100% for those who received both, offering new hope for breast cancer prevention.
A study published in The BMJ found that women diagnosed with early breast cancer have a low long-term risk of developing a second primary cancer, with risks varying by age and treatment. Researchers used data from the National Cancer Registration and Analysis Service to estimate these risks.
A majority of US women (19%) believe their healthcare providers have discussed the role of nutrition in preventing breast cancer. However, fewer women are aware of specific steps they can take to lower their breast cancer risk through diet.
A study published in iScience found that cells in breast tissues of women with African ancestry send cues promoting breast cancer growth. Researchers discovered that PZP cells activate epithelial cells, allowing them to invade surrounding tissue.
The ASCENT-04/KEYNOTE-D19 study shows that sacituzumab govitecan plus pembrolizumab improves progression-free survival and response rates compared to chemotherapy. Nearly 60% of patients responded, with durable responses lasting up to 16.6 months.
Patients with breast cancer detected through routine screening mammography have improved clinical outcomes, including lower odds of advanced stage breast cancer and death. In contrast, symptom-detected cases were more frequent in older women and had higher mortality rates.
A multi-center clinical trial found that Duavee, a menopause drug, significantly reduced cell growth in breast tissue and was well-tolerated by participants. The study suggests that Duavee may offer a promising alternative for women at elevated risk of invasive breast cancer due to personal or family history.
A new study published in Radiology found that abbreviated breast MRI is an effective screening method for women with extremely dense breasts, detecting cancer while reducing scan times by up to 80%. The abbreviated protocol retains a high level of diagnostic accuracy comparable to the full protocol MRI.
Researchers identified changes in stromal tissue associated with increased aggressive breast cancer risk and poorer survival rates among women with benign breast disease. The study used machine learning to detect subtle changes in breast tissue samples from over 9,000 women.
A new study identified six distinct breast tissue patterns associated with an increased risk of invasive breast cancer, particularly among Black women. The radiomic phenotypes may help predict the likelihood of false-negative mammograms or interval cancer diagnoses.
A UK study of 48,417 women found that significant weight gain after age 20 and late first pregnancy increase the risk of breast cancer. Women who experienced early first pregnancy were found to have greater weight gain during adulthood than those with a late first pregnancy.
Researchers analyzed medical claims data to identify increased risks of heart failure, atrial fibrillation, and fractures among breast cancer survivors. The study highlights the importance of preventive care for these individuals.
A new study published in The Journal of Internal Medicine found that having an unhealthy metabolic profile increases the risk of breast cancer recurrence by 69% and subsequent breast cancer mortality by 83% among survivors. This association was consistent across Europe, North America, and Asia.
A study published in Plastic and Reconstructive Surgery reports that breast-conserving therapy, including radiation therapy, leads to progressive breast volume loss over time. Women with larger breasts experience greater total breast shrinkage, highlighting the need to discuss long-term changes in breast volume with patients.
A new study found that interval cancers, which are detected between two screening sessions, account for 30% of all breast cancers. Women with high breast density, hormone therapy, and a family history of breast cancer are at increased risk. More frequent or improved screening methods could significantly improve early detection rates.
A new study by Boston University researchers reveals that insulin resistance increases the aggressiveness and brain metastasis of triple-negative breast cancer. The findings highlight the need for personalized treatments and monitoring for patients with obesity-driven diabetes and aggressive breast cancer.
Breast cancer mortality rates have stopped decreasing in two age groups: women under 40 and those over 74. This shift is attributed to an increase in stage IV breast cancers at diagnosis, leading to poor prognoses.
A study published in Plastic and Reconstructive Surgery reports that women who undergo breast-conserving therapy (BCT) experience improved sexual well-being compared to those who receive post-mastectomy breast reconstruction (PMBR). Scores on a sexual well-being subscale were consistently higher for BCT patients, with average scores 7....
A new treatment, datopotamab deruxtecan, has been approved by the FDA for people with metastatic ER-positive breast cancer. Researchers at Memorial Sloan Kettering Cancer Center have also discovered a new strategy to overcome resistance in prostate cancers, suggesting that targeting mTOR may restore sensitivity. Additionally, an MSK re...
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
Artificial intelligence is enhancing breast cancer risk prediction through mammographic analysis, uncovering key features that predict breast cancer risk. These AI-generated features may inform personalized screening strategies, such as more frequent or less frequent screenings for women at high or low risk of breast cancer.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
Researchers have identified a new therapeutic strategy to enhance the sensitivity of aggressive breast cancer cells to hormonal therapies. By inhibiting the HDAC6 protein, they were able to boost progesterone receptor levels and potentially reverse resistance to hormonal treatments.
The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, the incidence of breast cancer has continued to rise, with a 1% annual increase from 2012-2021.
Early-stage HR+ breast cancer survivors experience weight gain, particularly those with healthy BMI or overweight at diagnosis. Black women have higher rates of obesity and related comorbidities compared to White women, leading to a 40% higher breast cancer mortality rate.
A new study from NRG Oncology found that whole-breast irradiation (WBI) was not statistically equivalent to accelerated partial-breast irradiation (APBI) in local tumor control. The QOL sub-study also showed that APBI may be preferred by some patients due to reduced fatigue and extended treatment time.
Two studies found breastfeeding after breast cancer diagnosis is safe and feasible for young patients with specific genetic variations, as well as hormone receptor-positive breast cancer survivors. A third study shows a telephone-based coaching program can significantly increase physical activity in overweight patients, potentially imp...
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
A new study provides a detailed map of healthy breast cells, shedding light on how breast cancer develops and the genetic ancestry-dependent variability in breast tissue. The research aims to identify new treatment targets and improve understanding of breast cancer development.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
A study found that nearly 20% of breast cancer survivors experience excess weight gain of more than 10% over six years. Factors associated with this weight gain include lower body weight, younger age, hormone-positive breast cancer, and certain genetic mutations.
Researchers have developed a targeted therapy for triple negative breast cancer by linking an antibody to a cell-killing drug. This approach may reduce side effects and improve patient outcomes for women diagnosed with this aggressive form of the disease.
Higher childhood body size may reduce breast cancer risk by forming less dense breast tissue, which is a known risk factor for the disease. The study found that over 50% of the protective effect is explained by changes in dense breast tissue.
A recent analysis of WHI findings indicates that MetS and obesity each have different associations with breast cancer subtypes and mortality risk. Women with higher MetS scores are at a higher risk of poor-prognosis, estrogen receptor-positive, progesterone receptor-negative breast cancers.
A study published in the Canadian Association of Radiologists Journal shows an increase in breast cancer diagnoses among females in their Twenties, Thirties, and Forties. Younger women are more likely to be diagnosed at later stages and with more aggressive cancer.
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
A new study published in JNCI Cancer Spectrum found that following a healthy diet, such as the DASH diet, lowers the risk of cardiovascular disease in breast cancer survivors. Women whose diets were most similar to DASH had a 47% lower risk of heart failure and other cardiovascular-related events.
The new Lancet Commission on Breast Cancer warns that people with metastatic breast cancer have been often forgotten, highlighting key barriers and inequities in healthcare. The report advocates for six crucial areas for change, including improving early diagnosis programs and communication with patients.
A team of researchers from Hiroshima University has discovered a molecule called AIbZIP that promotes the production of cancer cells in triple-negative breast cancer. This finding may lead to new therapeutic targets for the treatment of this aggressive form of breast cancer.